By Lynn Cowan 
 

Times are slow when it comes to issuing stock, and it isn't just IPOs that are feeling the effects.

Follow-on deals--when new shares from existing public companies are sold to the public--have experienced a decline this year, both in numbers and in the amount of money raised, according to data from Ipreo, a capital-markets research firm. Follow-on offerings can include shares being sold by insiders, such as venture capital or private-equity shops, or from the company itself. What are known as secondary offerings, by contrast, involve only insiders selling stock.

The number of follow-ons is down 15.3% this year, while proceeds raised are 21.9% below last year's pace, by Ipreo's count. The largest amount raised this year was the $6 billion brought in through American International Group Inc. (AIG) shares sold by the U.S. Treasury in March. The U.S. sold another $5.7 billion worth of shares in a May offering. In the first six months of 2011, AIG was also the biggest follow-on issuer. The Treasury sold $8.7 billion worth of shares in May of last year.

The Treasury took a majority stake in the insurer in 2008 as part of its Troubled Asset Relief Program and is selling its holdings to recoup taxpayer dollars that helped bail out the company.

Other follow-on offerings this year have spanned a range of industries, from discount retailer Dollar General Corp.'s (DG) $1.6 billion raise in June to pharmaceutical developer Corcept Therapeutics Inc.'s (CORT) $47 million raise earlier this week.

Follow-on offerings are sensitive to broader market conditions, and the volatility and market declines experienced this year haven't produced the ideal climate for stock sales. But, unlike the IPO market, which came to a halt in the five weeks following Facebook Inc.'s (FB) disappointing debut, nearly 50 follow-ons were still able to launch. Follow-ons are perceived as being less risky than IPOs, since the issuers already have a history of earnings reports and stock-trading patterns.

"People still are looking for opportunities to make money. They are looking toward names they are more comfortable with and that have a track record of performance," said David Hermer, head of equity-capital markets for the Americas region at Credit Suisse Group.

That isn't to say the follow-on market isn't feeling pressure from investors, primarily comprised of institutions such as pension funds and mutual funds. The average price discount on deals widened to 8.7% in June from 6.7% in May, according to Ipreo, although on a year-to-date basis, the average discount of 6% is actually lower than the 6.4% seen at this same point in 2011, thanks to wider discounts earlier in 2011.

"As more gets done, one would hope the discounts would come back in," said Steve Gillette, a partner at law firm Jones Day's Silicon Valley office.

Write to Lynn Cowan at lynn.cowan@dowjones.com.

Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Corcept Therapeutics Charts.
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Corcept Therapeutics Charts.